Taylor Jensen, Director, Research and Development, Sequenom (a LabCorp Company)

Dr. Jensen serves as Director of Research and Development at Sequenom, a wholly owned subsidiary of Laboratory Corporation of America. He joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Since that time, Dr. Jensen has been involved in numerous assay development efforts focused on the detection of genetic and epigenetic changes in cfDNA for use in both the prenatal and oncology fields with the overarching goal of utilizing these aberrations to improve human health. Prior to joining Sequenom, Dr. Jensen received his B.S. degree in biology from Utah State University and completed his PhD in Pharmacology and Toxicology from the University of Arizona.